[{"orgOrder":0,"company":"Viatris","sponsor":"Beximco Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viatris \/ Beximco Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Beximco Pharmaceuticals"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"OnabotulinumtoxinA","moa":"Ach release","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Viatris","amount2":0.10000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Viatris \/ Mylan","highestDevelopmentStatusID":"1","companyTruncated":"Viatris \/ Mylan"},{"orgOrder":0,"company":"Viatris","sponsor":"Mapi Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Viatris","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Viatris \/ Mylan","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Mylan"},{"orgOrder":0,"company":"Somerset Pharmaceuticals Inc","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Sulfamethoxazole","moa":"Dihydropteroate synthase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Somerset Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Somerset Pharmaceuticals Inc \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Somerset Pharmaceuticals Inc \/ Premier"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Fondaparinux Sodium","moa":"Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Viatris","amount2":0.76000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.76000000000000001,"dosageForm":"","sponsorNew":"Viatris \/ Mylan","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Mylan"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Clinton Health Access Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Clinton Health Access Initiative","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Clinton Health Access Initiative"},{"orgOrder":0,"company":"Viatris","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Amlodipine","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Viatris","amount2":12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":12,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Viatris \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Viatris","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Termination","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Astellas"},{"orgOrder":0,"company":"Viatris","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Termination","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Immunology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Astellas"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","graph1":"Oncology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Biocon"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Biocon"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"Viatris \/ Kindeva","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Kindeva"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Famy Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Oyster Point Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Varenicline Tartrate","moa":"ACh receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.41999999999999998,"dosageForm":"Spray","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Viatris","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.10000000000000001,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Viatris","amount2":3.3399999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":3.3399999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Biocon"},{"orgOrder":0,"company":"Viatris","sponsor":"Oyster Point Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Varenicline Tartrate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Viatris","amount2":0.41999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.41999999999999998,"dosageForm":"Spray","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Famy Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Viatris","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Insulin Glargine","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Viatris","amount2":3.3399999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":3.3399999999999999,"dosageForm":"Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Biocon"},{"orgOrder":0,"company":"Viatris","sponsor":"InDex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Cobitolimod","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Viatris","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.050000000000000003,"dosageForm":"Enema","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Mapi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Viatris \/ Mapi Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Mapi Pharma"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Abacavir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Ocuphire Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Dydrogesterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Viatris","amount2":3.3700000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":3.3700000000000001,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Theramex"},{"orgOrder":0,"company":"Viatris","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Dydrogesterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Viatris \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Theramex"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Revefenacin","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Selatogrel","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Selatogrel","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"14","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Venlafaxine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Lexicon pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sotagliflozin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"14","companyTruncated":"Viatris \/ Viatris"}]
Find Clinical Drug Pipeline Developments & Deals by Viatris
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
